Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of tanespimycin in treating
young patients with recurrent or refractory leukemia or selected solid tumors. Drugs used in
chemotherapy, such as tanespimycin, work in different ways to stop cancer cells from dividing
so they stop growing or die.